N/A N=100 Point of Care Testing in Pediatric Patients Undergoing Major Surgery
Spinal Fusion · Cardiopulmonary Bypass
Primary: International Normalized Ratio (INR) on CoaguChek — 1.11; 4.6 ratio
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=13 Evaluation of Novel Point of Care Coagulation System in Pregnant Women
Hemorrhage · Coagulation Delay
Primary: Correlation of Fibrinogen in mg/dL Concentration With Clot Strength (CS hPa) and Fibrinogen Contribution to Clot (FCS hPa) of Point of the Care Quantra System. — 494…
N/A N=200 Novel Biomarkers of Thrombotic Risk
Myocardial Infarction
Primary: Cardiovascular Event - Myocardial Infarction, Stroke, Death — 17; 6 Participants — p=0.007
N/A N=114 Comparison of Rapid Thrombelastography and Conventional Coagulation Testing for Haemostatic Resuscitation in Trauma
Acute Coagulopathy
Primary: 28 Day In-hospital Mortality — 20; 11 participants — p=0.04
N/A N=52 Hemosonics- VCU Cardiac Surgery Clinical Study
Cardiopulmonary Bypass
Primary: Clot Time — 4.9; 3.3 min — p=<0.001
Phase 2 N=160 Prothrombin Times Outside the Therapeutic Range in Otherwise Stable Patients
Atrial Fibrillation · Venous Thromboembolism · Ischemic Stroke
Primary: Number of Patients With Prothrombin Time Results Within the Therapeutic Range After 2 Weeks — 48; 45 participants
N/A N=879 Reference Intervals of Complete Blood Count and Coagulation Tests in Pregnant Women at Hung Vuong Hospital
Pregnancy Related
Primary: Trimester Specific Prothrombin Time Reference Interval — 11.40; 10.60; 10.40 seconds
N/A N=24 Evaluation of the Accuracy of the Hemochron Signature Elite Point of Care Device Compared With Laboratory Assay
Blood Coagulation Tests
Primary: The International Normalised Ratio (INR) Will be Measured by the Laboratory Assay and the Hemochron Signature Elite Device. — 23 Participants
N/A N=51 Thromboelastography-derived Functional Fibrinogen Levels
Focus of Study · Coagulation Status of Cardiac Surgery Patient · Reducing Excess Blood Transfusion
Primary: Change in Thromboelastography-derived Functional Fibrinogen Level (FLEV) — -1.1 mg/dL
N/A N=30 Evaluation of a New Sonoclot Device for Heparin Management in Cardiac Surgery
Diagnostic Techniques and Procedures · Cardiac Surgical Procedure
Primary: Kaolin-activated Clotting Time — 309 seconds
Phase 3 N=465 Coagulopathy of COVID-19: A Pragmatic Randomized Controlled Trial of Therapeutic Anticoagulation Versus Standard Care
COVID-19
Primary: Composite Outcome of ICU Admission, Non-invasive Positive Pressure Ventilation, Invasive Mechanical Ventilation, or All-cause Death up to 28 Days. — 37; 52 Participants
N/A N=25 Remote Home Prothrombin Time (PT)/International Normalized Ratio (INR) Monitoring and Patient Management System
Venous Thromboembolism
Primary: Time Spent Per PT/INR Monitoring Encounter — 19.4; 47 minutes
N/A N=25 In-vitro Study to Assess the Coagulation Effects of Exogenous Oxytocin Using Thromboelastography.
Anesthesia
Primary: r Time — 5.6; 4.2; 3.9; 6 minutes
N/A N=24 Coagulation Factor Changes Associated With Postpartum Hysterectomies
Obstetric Labor Complications · Hemorrhage · Complications; Cesarean Section
Primary: Fibrinogen Level at 2 Hours After Delivery — 186; 418 mg/dL — p=<0.05
N/A N=911 In Vitro Diagnostic Test for DOAC in Urine
Anticoagulant Therapy
Primary: Accuracy of Factor Xa and Thrombin Inhibitors Pads of DOAC Dipstick From Urine Samples — 0.973; 0.993 percentage of correct responses — p=<0.05
N/A N=50 The Clinical Utility of Thrombelastography in Guiding Prophylaxis of Venous Thromboembolism Following Trauma
Venous Thromboembolism
Primary: Hypercoagulability — 16; 18 participants
Phase 2 N=250 Prolongation of the Interval Between Monitoring of Warfarin in Stable Patients
Atrial Fibrillation · Heart Valve Diseases · Venous Thrombosis
Primary: Primary Outcome Measure: Time in Therapeutic Range — 74.1; 71.6 percentage of time
Phase 4 N=20 Transfusion of Pathogen Reduced Cryoprecipitated Fibrinogen to Expedite Product Availability in Perioperative Bleeding
Hypofibrinogenemia · Bleeding
Primary: Total Number of RBCs Used Over Admission — 5.8; 6.7 RBC Units
Phase 2 N=14 Anticoagulation in Liver Fibrosis in Patients With Hepatitis C Virus Infection
Liver Fibrosis
Primary: Median Liver Stiffness Value — 7.70; 6.90 kPa — p=0.043
Phase 2 N=15 Human Fibrinogen - Pharmacokinetics
Fibrinogen Deficiency
Primary: Maximum Clot Firmness (MCF) — 0; 8.9 millimeters — p=<0.0001
N/A N=200 Improved Time in Therapeutic Range With Patient Self-Testing of Their INR Compared to Usual Care
Management of Anticoagulation
Primary: Mean Percentage of Time in Therapeutic Range — 48; 53 percentage of time — p=0.20
N/A N=246 Platelet Activity in Vascular Surgery and Cardiovascular Events
Cardiovascular Disease · Peripheral Artery Disease · Critical Limb Ischemia
Primary: Number of Patients in Which Platelet Activity Measurements Were Associated With Short-term Cardiovascular Events — 31; 16 participants
N/A N=20 Ventricular Assist Device Anti-Factor Xa (VAD ANTIX) Monitoring Study: a Prospective Randomized Feasibility Trial
Left Sided Heart Failure · Left Ventricular Assist Device · Anticoagulant Therapy
Primary: Nomogram Feasibility — 136; 112; 136; 111 Surveys — p=.45
Phase 3 N=216 Efficacy and Safety Study of BERIPLEX® P/N (Kcentra) Compared With Plasma in Patients With Acute Major Bleeding Caused by Anticoagulant Therapy
Blood Coagulation Disorders · Acute Major Bleeding
Primary: Percentage of Participants Achieving Hemostatic Efficacy of Stopping an Ongoing Major Bleed — 72.4; 65.4 percentage of participants
Phase 3 N=200 Study of Octaplex (Human Prothrombin Complex Concentrate) and Fresh Frozen Plasma in Patients Under Vitamin K Therapy Antagonist Needing Urgent Surgery or Invasive Procedures
Reversal of Anticoagulant Treatment
Primary: INR Response — 74; 31 Participants
N/A N=123 Clinical Performance Evaluation of Pefakit® PiCT® UC In Vitro Diagnostic Medical Device
Thromboembolic Events
Primary: Overall Sensitivity and Specificity of Pefakit and Hemosil. — 83.3; 77; 81.5; 59.3 percentage of cases
Early Phase 1 N=28 RAS and Coagulopathy in COVID19
COVID
Primary: Coagulopathy Associated With COVID-19 — -313; -129.5 ng/mL FEU
Phase 3 N=57 Does Plasma Reduce Bleeding in Patients Undergoing Invasive Procedures
Blood Coagulation Disorders · Hemorrhage
Primary: Change in Hemoglobin Level — -0.6; -0.4 g/dL
N/A N=334 Platelet Reactivity (High On-Treatment Platelet Reactivity) as Guidance for APT (Antiplatelet Therapy) Adjustment After PCI (Percutaneous Coronary Intervention)
PRU(Platelet Reactivity Unit) · APT(Antiplatelet Therapy) · HOTPR(High on Treat Platelet Reactivity)
Primary: Numbers of Participants With MACE(Major Adverse Cardiac Event) of Study Subjects — 1; 1; 2 numbers of participants with MACE — p=0.002
N/A N=68 Comparison of Blood Product Use and Bleeding Events During and After Endoscopic or Neurosurgical Procedures in Patients With Cirrhosis and Coagulopathy
Cirrhosis · Coagulopathy
Primary: Intra-operative Blood Loss — 2000; 3000 milliliters